Good evening. This snapshot of stories and roundup is recommended just for you, based on your interests and reading history. | | | | Carlos Campos meets with a patient last month in New Braunfels, Texas. (Ilana Panich-Linsman/For The Washington Post) | | | | | | |  What to know Carlos Campos, a Texas physician, has earned nearly $1 million promoting GLP-1 weight-loss drugs for Eli Lilly and Novo Nordisk. A Washington Post analysis found these companies paid over $270 million to prescribers since 2018. Critics warn of conflicts of interest and underappreciated side effects. The drugs' sales have surged, with Medicare now covering them, raising concerns about long-term costs and health impacts. Summary is AI-generated, newsroom-reviewed. | | | | | How was today's newsletter? | | | | | | | | |
Have a question? Ask the Post AI to learn more 
